Carboplatin/Durvalumab/Nab-paclitaxel/Tremelimumab Regimen

Preferred Label : Carboplatin/Durvalumab/Nab-paclitaxel/Tremelimumab Regimen;

NCIt synonyms : Carboplatin/Imjudo/Abraxane/Imfinzi; Tremelimumab/Durvalumab/Albumin-bound Paclitaxel/Carboplatin; Tremelimumab/Durvalumab/Nab-paclitaxel/Carboplatin; Imjudo/Imfinzi/Carboplatin/Abraxane; Carboplatin-Durvalumab-Nab-paclitaxel-Tremelimumab; Carboplatin/Durvalumab/Nab-paclitaxel/Tremelimumab; Imjudo/Imfinzi Plus Carboplatin/Nab-paclitaxel; Carboplatin/Imjudo/Nab-paclitaxel/Imfinzi; Carboplatin/Durvalumab/Nab-paclitaxel/Tremelimumab-actl;

NCIt related terms : Carboplatin, nab-Paclitaxel, Durvalumab, Tremelimumab;

NCIt definition : A regimen consisting of carboplatin, durvalumab, nab-paclitaxel and tremelimumab that may be used in the treatment of non-small cell lung cancer (NSCLC).;

NCI Metathesaurus CUI : CL1922491;

Codes from synonyms : 112571;

Details

Origin ID

C203690;

UMLS CUI

C5909402;

Semantic type(s)
- Therapeutic or Preventive Procedure [UMLS semantic type]
chemotherapy_regimen_has_component
- Carboplatin [NCIt concept]
- Durvalumab [NCIt concept]
- Nab-paclitaxel [NCIt concept]
- Tremelimumab [NCIt concept]
concept_is_in_subset
- HemOnc Regimen Terminology [NCIt concept]
- Multi-agent Therapeutic Regimens [NCIt concept]
- Pharmacotherapy Regimens [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients